Why is Panacea Biotec falling/rising?

As of 01-Aug, Panacea Biotec Ltd is experiencing a decline in its stock price, currently at Rs 400.65, which represents a decrease of Rs 2.7 or 0.67%. The stock has been underperforming recently, having fallen for three consecutive days with a total decline of 5.74%. It is trading below all its moving averages, indicating a bearish trend. Despite outperforming its sector by 2.49% today, the stock's one-week performance shows a drop of 3.98%, while its one-month return is down 2.44%. The company is facing significant challenges, including operating losses and a weak long-term fundamental strength, as evidenced by a staggering annual decline in operating profit of 225.52% over the past five years. Additionally, the company's ability to service its debt is compromised, reflected in a negative EBIT to Interest ratio of -12.51, and a recent PAT of Rs -29.60 crore, which has fallen by 525.8%.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has only declined by 1.06% over the past week. While Panacea Biotec has generated impressive returns of 189.28% over the past year, its profits have decreased by 33.8%, raising concerns among investors. The pharmaceuticals and drugs sector has also faced a downturn, falling by 3.26%. Furthermore, the lack of investment from domestic mutual funds, which hold 0% of the company, suggests a lack of confidence in the stock's valuation or business prospects. Overall, the combination of poor financial performance, negative investor sentiment, and sector-wide challenges contributes to the stock's current downward trajectory.